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Context:Mutations in the electron donor enzyme P450 oxidoreductase (POR) result in congenital
adrenal hyperplasia with apparent combined 17-hydroxylase/17,20 lyase and 21-hydroxylase de-
ficiencies, also termed P450 oxidoreductase deficiency (PORD). Major clinical features present in
PORD are disordered sex development in affected individuals of both sexes, glucocorticoid defi-
ciency, and multiple skeletal malformations.
Objective: Theobjective of the studywas to establish anoninvasive approach toprenatal diagnosis
of PORD including assessment of malformation severity to facilitate optimized prenatal diagnosis
and timely treatment.
Design: We analyzed 20 pregnancies with children homozygous or compound heterozygous for
disease-causing PORmutations and 1 pregnancy with a child carrying a heterozygous PORmuta-
tion by recording clinical and biochemical presentations and fetal ultrasound findings. In 4 of the
pregnancies (3 homozygous and 1 heterozygous for disease-causing POR mutations), prenatal
analysis of steroidmetabolite excretion inmaternal urinewas carried out by gas chromatography/
mass spectrometry during gestational weeks 11–23.
Results: Pregnancy complications in our cohort included maternal virilization (6 of 20) with onset
in the second trimester. Seven pregnant women presented with low unconjugated estriol at pre-
natal screening (triple or quadruple antenatal screening test). Overt dysmorphic features were
noted in 19 of the 20 babies at birth but observed in only 5 by prenatal ultrasound. These 5 had the
most severe malformation phenotypes and poor outcome, whereas the other babies showed
normal development. Steroid profiling of maternal urine revealed significantly increased steroids
of fetal origin, namely the pregnenolone metabolite epiallopregnanediol and the androgen me-
tabolite androsterone, with concomitant low values for estriol. Diagnostic steroid ratios conclu-
sively indicatedPORDasearly asgestationalweek12. In theheterozygouspregnancy, steroid ratios
were only slightly elevated and estriol excretion was normal.
Conclusion:Prenatal diagnosis in PORD is readily establishedviaurinary steroidmetabolite analysis
of maternal urine. Visible malformations at prenatal ultrasound predict a severe malformation
phenotype. (J Clin Endocrinol Metab 98: E528–E536, 2013)
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Abbreviations: CYP, cytochrome P450; CYP17A1, 17-hydroxylase/17,20-lyase;
CYP19A1, P450 aromatase; CYP21A2, 21-hydroxylase; DHEA, dehydroepiandrosterone;
DSD, disorder of sex development; EpialloPD, epiallopregnanediol; GC/MS, gas chroma-
tography/mass spectrometry; PD, pregnanediol; POR, P450 oxidoreductase; PORD, POR
deficiency; SDS, SD score; TOP, termination of pregnancy.
J C E M O N L I N E
A d v a n c e s i n G e n e t i c s — E n d o c r i n e C a r e
E528 jcem.endojournals.org J Clin Endocrinol Metab, March 2013, 98(3):E528–E536
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 27 June 2014. at 06:29 For personal use only. No other uses without permission. . All rights reserved.
Congenital adrenal hyperplasia due to P450 oxi-doreductase deficiency (PORD) is a condition with
autosomal recessive inheritance, caused by mutations in
the P450 oxidoreductase (POR) gene (1–3). PORD pa-
tients present with biochemical evidence of partial defi-
ciencies in 21-hydroxylase (CYP21A2) and 17-hydrox-
ylase/17,20-lyase (CYP17A1) activities and manifest
clinically in many but not all cases with disorder of sex
development (DSD) inboth sexes; glucocorticoiddeficien-
cy; and skeletal malformations including craniosynosto-
sis, midface hypoplasia, radiohumeral synostosis, and
phalangeal abnormalities (4–8). POR is the crucial elec-
tron donor to all microsomal cytochrome P450 (CYP) en-
zymes including the steroidogenic enzymes CYP21A2,
CYP17A1, and P450 aromatase (CYP19A1), thus ex-
plaining the deficiencies in steroid synthesis observed in
patients with PORD (2–3). POR also serves as the
mandatory electron donor to squalene epoxidase and
14-lanosterol demethylase (CYP51A1) catalyzing im-
portant steps in cholesterol synthesis. Sterols are involved
in hedgehog-mediated regulation of fetal bone develop-
ment. Hence, decreased 14-lanosterol demethylase ac-
tivity as documented ex vivo in a patient with PORD (9)
may explain the observed skeletal malformation pheno-
type,which resembles that observedafter thedisruptionof
downstream processing of lanosterol by fluconazole (10–
13). Distinct POR mutations can differentially affect the
activities of electron-accepting CYP enzymes, a likely ex-
planation for the observed phenotypic variability (5,
14–16).
The prognosis and outcome of PORD patients relies
heavily on early diagnosis and timely treatment with op-
timal perinatal care including assessment of glucocorti-
coid replacement requirements as well as corrective treat-
ment of skeletal malformations and DSD manifestations.
Therefore, the aim of this study was to establish tools for
prenatal diagnosis and estimation of disease severity.
Subjects and Methods
Patients
We analyzed pregnancy data from 20 patients (8 males, 12
females)withgenetically confirmedPORDand1pregnancywith
a fetus carrying a heterozygous mutation in the POR gene. Four
of these pregnancies have been prospectively monitored (PORD
A, B, C, and the heterozygous babyD) and are described in detail
below.
PORD pregnancy A was the second pregnancy of healthy,
nonconsanguineous parents. Their first child (46,XX) was af-
fected by PORD, born with overt craniofacial malformations
and severely virilized external genitalia (Prader IV); a cosyntro-
pin test confirmedadrenal insufficiency.Thepregnancyhadbeen
complicated by signs of maternal androgen excess (acne from
gestational weeks 14 to 16 and maternal voice deepening noted
from week 24). Genetic analysis detected homozygous POR
p.A287P (g.29,556 GC) mutations, with both parents being
heterozygous carriers.
During the second pregnancy, the mother did not experience
signs of androgen excess. Prenatal ultrasound examinations for
detection of skeletal malformations were carried out every 4–6
weeks, showing normal fetal development without visible mal-
formations throughout the pregnancy. Amniocentesis was car-
ried out during the 16th week of gestation and direct sequencing
of amniocyteDNA revealed the same homozygous p.A287Pmu-
tation as in the first child; the karyotype was confirmed as
46,XY. After an otherwise uneventful pregnancy, labor initiated
spontaneously at gestational week 35. Birth weight was 2830 g
[0.9 SD score (SDS)], length was 53 cm (3.2 SDS), and head
circumference was 34 cm (1.4 SDS) (SDS according to British
1990 growth reference data). Initially the patient suffered from
respiratory distress and had to be referred to the neonatal inten-
sive care unit for continuous positive airway pressure ventilation
therapy. The baby had midface hypoplasia, a pear-shaped nose,
a soft palate cleft, and mild acrocephaly without overriding cra-
nial sutures and a mild left elbow contracture. Other malforma-
tions included arachnodactyly, rocker-bottom feet, and a nar-
row chest with mild pectus excavatum. The penis was of normal
size and the testes were bilaterally descended. He was started on
hydrocortisone replacement therapy in the first week of life. At
6 weeks of age, surgery for bilateral inguinal and umbilical her-
nias was performed. He underwent surgery for coronal and
metopic synostosis at age 6 months; the soft palate cleft was
repaired at 1 year of age. Postnatal growth and development
including cognitive function were normal.
PORD pregnancy B was the first pregnancy of healthy, non-
consanguineous parents. Routine prenatal ultrasound at 16
weeks revealed an abnormally shaped skull, bowed femora, bi-
lateral radioulnar synostosis, and ambiguous genitalia. Based on
the severe malformation phenotype, the parents decided for ter-
mination of pregnancy (TOP), whichwas carried out in the 25th
week of gestation. The postmortem on the fetus was consistent
with a severe malformation phenotype including coronal synos-
tosis, severe midface hypoplasia, bilateral radiohumeral synos-
tosis, and bowed femora (all confirmed on posttermination x-
ray, Figure 1A) as well as micropenis, absent scrotum, and
undescended testes. The karyotype was 46,XY.
Sequencing analysis of fetal DNA commenced after termina-
tion revealed compound heterozygosity for p.A287P and a
frameshift mutation I444fsX6 (g.31,146dupC).
PORD pregnancy C was the second pregnancy of healthy,
nonconsanguineous parents (same father as in the first preg-
nancy). The first pregnancy had resulted in a healthy baby girl.
The course of the second pregnancy was unremarkable, without
signs of maternal virilization. At 19 weeks’ gestation the triple
test (human chorionic gonadotropin, -fetoprotein, and uncon-
jugated estriol) showed undetectable levels of estriol (0.02 ng/
mL). At 20 weeks’ gestation, the following anomalies were de-
tected by prenatal ultrasound: bowed femurs bilaterally,
craniosynostosis, intrauterine growth retardation, and abnor-
mal scissoring of the lower extremities (right foot positioned on
left flank). A fetal magnetic resonance imaging did confirm the
above. The amniocentesis performed at gestational week 20 re-
vealed a female karyotype (46, XX). In gestational week 39, the
baby was delivered by cesarean section without any complica-
tions.After birth the baby experienced respiratory distress due to
J Clin Endocrinol Metab, March 2013, 98(3):E528–E536 jcem.endojournals.org E529
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 27 June 2014. at 06:29 For personal use only. No other uses without permission. . All rights reserved.
a choanal stenosis [Apgar indices 8 at 1 minute, 9 at 5 minutes;
birth weight 2610 g (1.16 SDS), length 48 cm (1.67 SDS),
head circumference 31 cm (2.89 SDS)] (SDS according to Brit-
ish 1990 growth reference data). Postnatally the following
malformations were evident: craniosynostosis without hydro-
cephalus (Figure 1B), bilateral choanal stenosis, craniovertebral
junction deformity, bilateral vesicoureteral reflux, bilateral hy-
dronephrosis, contractures of the fingers and toes, arachnodac-
tyly, humeroradial-ulnar synostosis of the upper extremities,
shortened femurs, and humeri bilaterally. The external genitalia
had normal female appearance. The baby was admitted to the
intensive care unit and initially ventilated; concurrently hydro-
cortisone replacement was initiated. On day 69 she died due to
respiratory insufficiency, most likely as a consequence of central
apnea. Genetic analysis revealed compound heterozygous POR
mutations (p.A287P/p.Q455Rfs166X).
Heterozygous PORDpregnancyDwas the second pregnancy
of a consanguineous Pakistani couple. The first baby (46, XY)
had presented at delivery with a dysmorphic face including fron-
tal bossing, hypotelorism, proptosis, low nasal bridge, short col-
umella, pronounced philtrum, and small, low-set ears. Other
malformations at birth included bilateral radiohumeral synos-
tosis and arachnodactyly. During the first trimester of preg-
nancy, the mother had started to develop hirsutism, resolving
after delivery. POR sequencing in the index child revealed a
homozygous p.R498P mutation.
Because of this history, the second pregnancy was closely
monitored by ultrasound, but no malformations could be de-
tected. Chorionic villous sampling during gestational week 11
revealed a 46,XX karyotype. The baby was well and healthy at
delivery, with no sign of malformations; genetic analysis after
birth revealed heterozygosity for p.R498P.
PORD malformation score
The clinicalmalformation phenotypewas assessed after birth
using a scoring algorithmwe recently developed (8). In brief, this
score assesses the absence or presence of 6 different types of
malformations: midface hypoplasia, craniosynostosis, phalan-
geal malformations, large joint synostoses, femoral bowing, and
additional malformations. The severity of each malformation is
graded on a scale ranging from 0 (not present), 1 (mild), 2 (se-
vere), to 3 (severe with additional complications). Theminimum
of the total PORD malformation score is 0 (no malformations),
and the maximum score is 16 (most severe malformation
phenotype).
Urinary steroid profiling
Urinary steroid metabolite excretion was analyzed by gas
chromatography/mass spectrometry (GC/MS). Characteriza-
tion and quantification of all excreted steroids has been previ-
ously established in a longitudinal study of a pregnancy with a
PORD fetus (17). This allowed designation of key analytes for
diagnosis of the condition by the development of an abbreviated
selected ionmonitoringquantitativemethod for their analysis. In
the 4 prospective PORD pregnancies followed up, maternal
urine for steroidmetabolite assessmentwas collected during ges-
tational weeks 12, 22, and 28 (PORD A), 23 (PORD B), 20
(PORD C), and 11 (heterozygous PORD pregnancy D), respec-
tively, and results were compared with the urinary steroid pro-
files from60apparentlynormalpregnanciesof gestationalweeks
15–23.
Results
Prenatal maternal and fetal findings
Overall, 7 of 20 pregnancies with a baby affected by
PORDwere complicated by signs ofmaternal virilization,
Figure 1. A, An x-ray radiograph performed at postmortem after the
termination of pregnancy PORD B at gestational week 25; note the
abnormally shaped skull, thin ribs, ankylosis of both elbow joints
(radioulnar synostosis), and bilateral bowed femora. B, Magnetic
resonance imaging of the head of patient PORD B on postnatal day 2,
illustrating the pronounced turricephaly consequent to PORD-
associated craniosynostosis.
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which usuallymanifested during the second trimester (Ta-
ble 1). Clinical signs and symptoms included acne, hirsut-
ism, and deepening of the voice, all resolving within a few
weeks after delivery. The occurrence of prenatal maternal
virilization did not show any conclusive correlation to
genotype or sex of the affected child. In 7 pregnancies a
low unconjugated estriol were found at routine prenatal
screening (triple or quadruple antenatal screening test)
during gestationalweeks 14–19 (cases 2, 3, 15, 17, PORD
A, PORD B, and PORD C).
Prenatal ultrasound detected skeletal malformations in
5 of the 20 PORD pregnancies (Table 1), in all cases de-
scribing clearly visible bowed femora. These 5 included
the above-described PORDpregnancies B andDand cases
1–3 (Table 1). In case 1, bilaterally angulated femorawere
detected for the first time at gestational week 21 and a
prominence of the forehead in addition to short and bent
femora at gestational week 25. In case 2, ultrasound
showed bowed femora and flexed distal limb joints of the
extremities at gestationalweek 16. In case 3, ultrasound in
gestational week 17 revealed a flattened nasal bridge, low
set ears, abnormal hand posturing, ambiguous genitalia,
and bowed humeri, femora and tibiae.
However, despite this low detection rate by prenatal
ultrasound, at birth all 20 PORD cases presented with
overt skeletal malformations; the median PORD malfor-
mation score of the cohort was 7.5, ranging from 4 to 15.
Of note, themedianmalformation score in the 15 patients
without evidence of malformations on prenatal ultra-
sound was 6 (range 0–10), ie, spanning from absent to
mild and moderate malformations. By contrast, the 5 pa-
tients with prenatally detected malformations presented
with the most severe skeletal malformation phenotypes
(all scores 10, median score 15) (Table 1). Of these 5
pregnancies, 1 ended after the termination of pregnancy
because of the severity of the observed malformations.
Threepatients died, due to recurrent respiratory infections
(case 1), accidental displacement of the tracheostomy tube
TABLE 1. Prenatal and Postnatal Presentation in 19 Patients Affected by PORD
Patient
Number Genotype Karyotype
Malformations
Detected by
Prenatal
Ultrasound
Total
Malformation
Score at
Birtha
Maternal
Androgen
Excess
DSD
Detected
by
Prenatal
Ultrasound
DSD
Evident
at
Birth Outcome
Follow-Up
Period
1 IVS7  2dupT/
p.Q455RfsX90
XY Y 15 N N Y Death at 19 mo 19 mo
2 p.A287P/ IVS6-2AT XY Y 15 Y Y Y Developmental
delay, death at
age 2 y
2 y
3 p.A287P/ IVS6-2AT XX Y 15 Y N N Delayed motor and
speech
development
23 mo
PORD B p.A287P/p.I444HfsX6 XY Y >10b n.d. Y Y TOP gestational wk
25
TOP gestational
wk 25c
PORD C p.A287P/p.Q455Rfs166X XX Y 12 N N N Death at d 69 69 d
4 p.A287P/p.V472AfsX102 XY N 10 N N Y Conductive
hearing loss,
normal
intelligence
11 y
5 p.A287P/IVS8  1GA XX N 9 N N Y Normalc 11 y
6 p.A287P/p.G188V191dup XY N 9 Y N Y Delayed motor and
speech
development
23 mo
7 p.A287P/ XX N 9 Y N Y Normal 9 y
PORD A p.A287P/p.A287P XY N 8 N N N Normal 4 y
8 p.R498P/p.R498P XX N 7 Y N N Normal 1.5 y
9 p.A287P/p.A287P XX N 7 Y N Y Normal 6 y
10 p.A287P/p.H628P XX N 7 N N Y Conductive
hearing loss at
age 4 y, slightly
delayed
development
9 y
11 p.A287P/p.A287P XX N 5 N N Y Normal 14 y
12 p.Y376 LfsX74/p.T142A XX N 5 N N N Normal 20 y
13 p.R457H/p.A287P XX N 4 N N Y Normal 16 y
14 p.A287P/Del exU1-1 XX N 4 N N N Normal 3.5 y
15 p.C569Y/p.Y181D XX N 4 N N Y Normal 4 y
16 p.A287P/p.A287P XY N 4 N N N Normal 7 y
17 p.C569Y/p.Y181D XY N 0 Y N N Normal 2 y
Abbreviations: E3, estriol; , no mutation detected; N, no; n.d., not determined; Y, yes. Bold indicates cases with visible malformations on
prenatal ultrasound and a total malformation score above 10.
a For a detailed description of the PORD malformation score, please see published reference (8).
b The malformation score for case PORD B is likely to be underestimated as scoring based on postmortem report rather than clinical examination.
c Normal, normal postnatal development in terms of growth, speech, motor, and cognitive function.
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(case 2), and respiratory failure due to central apnea
(PORD C). The fifth patient survived but suffered from
delayedmotor and cognitive development. By contrast, all
15 patientswith amild to intermediatemalformation phe-
notype survived with a normal functional outcome with
regard to growth, motor, speech, and cognitive develop-
ment (Table 1). Characteristic malformations docu-
mented by prenatal ultrasound in the severely affected
group were a bowed femora and an abnormally shaped
skull,whichwas documented in all 5 patients. By contrast,
only 2 of the 15 patients in themildermalformation group
(cases 6 and 8, Table 1) had bowed femora and only 1 of
15 (case 6) had amidfacemalformation phenotype of sim-
ilar severity to the severe malformation group; in both
cases these had not been detected prenatally, and their
total malformation scores were lower than in the 5 pa-
tients with the most severe malformation phenotype
(Table 1).
Urinary steroid profiling during pregnancy
Four pregnancies, PORD pregnancies A, B, and C and
the heterozygous pregnancy D, were monitored prospec-
tively with GC/MS analysis of maternal urine collected
between gestational weeks 11 and 23. This revealed sig-
nificant reduction in the excretion of estriol in the PORD
pregnancies, which in a normal pregnancy represents the
second most important end product of fetoplacental ste-
roid synthesis, after the progesterone metabolite preg-
nanediol (PD). The very high PD to estriol ratio in the 3
PORDpregnancies (Figure 2A) illustrates the pronounced
estriol deficiency. All 3 mothers showed markedly in-
creased excretion of the pregnenolone metabolite epiallo-
pregnanediol (EpialloPD), which is usually found in only
trace amounts in normal pregnancies. Consequently, the
EpialloPD to estriol ratios in the 3 affected pregnancies
were extremely elevated as comparedwith normal preg-
nancies (Figure 2B). The possible attenuated aromati-
zation of 16-hydroxyandrostenedione in the estriol
biosynthetic pathway would be represented by an in-
creased ratio of its metabolite 16-hydroxyandros-
terone to estriol, and this was the case in the 3 PORD
pregnancies studied (Figure 2C).
A further hallmark of the pregnancies affected by
PORDwas the overproduction of 5-reduced androgens,
reflected by highly increased excretion of the 5-reduced
androgen metabolite androsterone. This excess is most
easily represented by relating its excretion to that of its
5-epimer etiocholanolone, ie, the androsterone to etio-
cholanolone ratio. These ratio valueswere very high in the
3 PORD pregnancies as compared with normal pregnan-
cies (Figure 2D).
The typical features of PORD were identified in all
urine samples collected in the 3 affected pregnancies dur-
ing gestational weeks 12–28. All maternal steroid metab-
olites in urine normalized after delivery (data not shown),
consistent with a fetal source of abnormality during
pregnancy.
In the heterozygous pregnancyD, the above-mentioned
pathogenic urinarymetabolite ratios for PORDwere only
slightly elevated, and the estriol concentration was com-
pletely normal.
Discussion
Analysis of the course of 20 pregnancies with fetuses af-
fected by PORDand 1 pregnancy heterozygous for aPOR
mutation revealed 3 cardinal features indicative of the
presence of the disorder that may be evident prenatally:
maternal virilization, severe bonemalformations detected
by fetal ultrasound, and, invariably in the prospectively
monitored cases, a distinctly altered steroid metabolite
excretion in maternal urine indicative of PORD from ges-
tational week 12 onward. Remarkably, these changes
were uniformly present in all affected pregnancies and did
not vary as a function of genotype or phenotype, similar to
our previous experience with urine GC/MS analysis in
affected patients (8).
The characteristically low maternal urinary estriol ex-
cretion during the affected pregnancies was mirrored by
the finding of low serum estriol in the antenatal multiple
marker screening test carriedout in7of thepatients.These
findingswere similar to those in the2previously published
prenatal cases, describing low urinary and serum estriol,
respectively (17, 18). The maternal blood screening test is
usually performed between the 16th and 18th week of
pregnancy. The triple test comprises measurement of se-
rum -fetoprotein, human chorionic gonadotropin, and
estriol, but a quad test is gaining popularity and also in-
cludes inhibin A. The primary object of the screening test
is for detection of neural tube defects and Down’s syn-
drome (19, 20).
In a physiological pregnancy, estriol is generated in the
placenta from fetal dehydroepiandrosterone (DHEA), the
major product of fetal adrenal steroid synthesis (21). In
PORD, 3 enzymatic reactions that are involved in the
pathway leading to estriol synthesis are dependent on elec-
tron transfer byPORand thusmaybe compromised. First,
mutant POR results in impaired 17-hydroxylase/17,20-
lyase activity of CYP17A1. This consequently diminishes
the production of DHEA and downstream androgens,
thereby decreasing the amount of androgenic substrate
available for conversion to estriol by aromatase (Figure 3).
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Second, steroid 16-hydroxylase is required for the pro-
duction of 16-hydroxy-DHEA, but there is conflicting
evidence as to whether it has diminished activity due to
PORD. Finally, CYP19A1 aromatase activity itself could
be impaired by mutant POR, further contributing to low
estriol production, which again could show some vari-
ability in PORDwith distinct mutants having been shown
to have a differential impact on aromatase activity in vitro
(15). Impaired aromatase activity
would predictably result in an accu-
mulation of its immediate precursor
16-hydroxyandrostenedione and re-
flected in increased excretion of its
metabolite 16-hydroxyandrosterone.
These markers were modestly raised
in the pregnancies described here;
however, similar to our previously
reported case (17), these increases
were certainly not in the range that
would be expected in cases of aro-
matase deficiency due to CYP19A1
mutations. Thus, it appears that the
major determinant of low estriol in
PORD is reduced synthesis ofDHEA
due to impairment of 17,20-lyase
activity.
Low estriol on its own, however,
is a nonspecific marker that can be
associated with a number of condi-
tions, including several single gene
disorders underlying sterol and ste-
roid synthesis defects such as Smith-
Lemli-Opitzsyndrome,steroidsulfatase
deficiency,aromatasedeficiency,andse-
vere neonatal adrenal insufficiency due
to mutations in NR0B1 (dosage-sensi-
tive sex reversal-adrenal hypoplasia
congenita critical region on the X chro-
mosome, gene 1), NR5A1 (steroido-
genic factor 1), CYP11A1 (P450 side
chain cleavage enzyme), and TBX19
(TPIT,corticotrophspecificT-boxtran-
scription factor) (22–35). However,
here a distinct combination of low es-
triol and other fetal steroidmarkers en-
abledustomakethespecificdiagnosisof
PORDbasedontheanalysisofmaternal
urine at midpregnancy. Interestingly,
normal estriol in thepregnancywith the
heterozygousbabyclearlydistinguished
this pregnancy from the PORD preg-
nancies. In this case the PORD specific
ratios showed only very mild aberra-
tionsfromthecontrolcohortduetoanormalestriol, suggesting
that the baby was not affected by PORD. In addition to low
estriol,acharacteristicfindinginthePORDpregnancieswasthe
highly increased excretion of EpialloPD, a metabolite of fetal
pregnenolone,whichaccumulates inPORDdue to the concur-
rentimpairmentofCYP17A1andCYP21A2activities.Thus,in
PORD EpialloPD essentially replaces estriol as the major ter-
Figure 2. Proposed urine steroid metabolite ratios for a prenatal diagnosis of PORD. Illustrated
are normative values from gestational week 15 to week 23 (n  60) and 4 pregnancies with
affected PORD babies and 1 pregnancy with a heterozygous carrier. Panel A shows reduced
estriol relative to the excretion of the progesterone metabolite PD. Panel B shows increased value
of the EpialloPD to estriol ratio resulting from pregnenolone accumulation caused by attenuated
17-hydroxylase/17,20-lyase and decreased estriol production. Panel C shows increased 16-
hydroxyandrosterone excretion in relation to decreased estriol, indicative of the effect of mutant
POR on CYP19A1 aromatase activity. Panel D shows increased androsterone excretion compared
with etiocholanolone, indicative of alternative pathway androgen synthesis activity (2). Panel E
gives the abbreviation and systematic name of the urinary steroid metabolites and from which
they derive. The ratios denoted by an asterisk were obtained from a previously published report
on a patient (17).
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minalproductof fetaladrenalsteroidsynthesisandmetabolism
(17). Consequently, the altered fetal synthesis andmetabolism
in PORD pregnancy is most effectively documented by mea-
suring the urinary ratio of the abnormal end-product (Epial-
loPD) to the normal end-product (estriol). Importantly, we
could identifyall4prospectivelymonitoredPORDcasesby the
above-described urinary steroid ratios despite an appreciable
degreeofbiochemical variability observed inPORD.The iden-
tified ratios in our view reflect the key biochemical changes de-
tectable in prenatal PORD cases. However, further studies in
largercohortswillbeneededtofurthervalidateourfindings.We
should add that 2 other rare disorders, 17-hydroxylase defi-
ciency and cytochrome b5 deficiency, are also associated with
attenuated 17-hydroxylase/17,20 lyase and pregnenolone
build-up and may therefore give similar results regarding the
increased excretion of EpialloPD and low excretion of estriol.
However, in both conditions the maternal urine androsterone
to etiocholanolone ratio would be normal and not elevated as
was observed in PORD.
In normal pregnancies the excretion of the 2 epimeric
major androgen metabolites androsterone (5-reduced)
and etiocholanolone (5-reduced) is approximately
equivalent. Increased excretion of 5-reduced androgens
was demonstrated by the significantly elevated andros-
terone to etiocholanolone ratios in the PORDpregnancies
reportedhere andalso in thepreviously reported case (17),
providing a clue to the cause of maternal and female fetal
virilization in PORD. We have previously proposed that
this is caused by increased activity of an alternative an-
drogen biosynthetic pathway during fetal and early neo-
natal life (2), resulting in the increased production of an-
drosterone and 5-dihydrotestosterone. PORD results in
an accumulation of 17-hydroxypregnenolone and
17-hydroxyprogesterone that can enter the alternative
pathway (Figure 3). This pathway is accessed through a
5-reduced 17-hydroxypregnanolone intermediate
(3,17-dihydroxy-5-pregnan-20-one) that is a sub-
strate with higher affinity for the 17,20 lyase activity of
CYP17A1 than the other 17-hydroxysteroids, 17-hy-
droxypregnenolone and 17-hydroxyprogesterone (36).
In PORD, 5-reduced 17-hydroxypregnanolone interme-
diate conversion by 17,20 lyase via the alternative path-
way results in increased fetal production of androsterone,
which in turn can be converted to active androgen in the
fetoplacental unit, even while the conventional (classic)
androgen synthesis pathway is largely blocked. It is im-
portant to note that the presence of maternal virilization
was independent of genotype and other phenotypic char-
acteristics (Table 1) and, for example, was observed in 1
affected child but not in its sibling with the same genotype
(PORDpregnancyA). Future researchwill have to be con-
ducted to reveal the underlying mechanisms explaining
this disparity.
Most of the 20 patients we reported here underwent
only routine prenatal ultrasound because no malforma-
tions were suspected prior to birth. Anatomic ultrasound
performed in prenatal specialist centers in the second tri-
mester has a reported detection rate of approximately
70%–90% for fetal congenital abnormalities (37, 38).
Thus, one could assume that specializedmalformation ul-
trasound may have detected skeletal abnormalities in the
milder cases.However, this assumption contrastswith the
longitudinally documented findings in aPORDpregnancy
A in which the pregnancy was very closely monitored by
specialist ultrasound after the birth of an index patient
with multiple skeletal malformations of intermediate se-
verity. However, prenatal ultrasound failed to detect the
malformations in the second child, whichwere clearly vis-
Figure 3. Simplified representation of steroid synthesis and
metabolism in normal (A) and PORD pregnancies (B). The precise
locations of certain transformations, for example 5PD to EpialloPD are
unconfirmed. Chol, cholesterol; Preg, pregnenolone; 5PD,
pregnenediol (5-pregnene-3,20-diol); Prog, progesterone; 16OH-
DHEA-sulfate, 16-hydroxydehydroepiandrosterone sulfate; 16OH-4,
16-hydroxyandrostenedione; 517HP, EpialloPD 17-hydroxyallopregn-
anolone (5-pregnane-3,17-diol-20-one); An, androsterone; AD,
androstanediol (5-androstane-3,17-diol); DHT, 5-dihydrotesto-
sterone; 17OH-Preg, 17-hydroxypregnenolone; DHEA, dehydroepiandro-
sterone; 17OHP, 17-hydroxyprogesterone.
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ible after birth.Ofnote, in our cohort, prenatal ultrasound
seemed to indicate disease severity and long-termoutcome
in PORD. All 5 patients with the highest malformation
scores based on postnatal clinical assessment were found
to have skeletal malformations during routine prenatal
ultrasound examinations, whereas no malformations
were detected in the 15 patients with clinically interme-
diate or mild malformation phenotypes. This would sug-
gest that only the most severe PORD-related malforma-
tion phenotypes can be detected reliably by routine
prenatal ultrasound, and according to our data, these are
invariably associatedwith a poor prognosis, whereas chil-
drenwith intermediate,mild, or absentmalformationphe-
notypes had a good clinical outcome.
The option of prenatal diagnosis always comes with
ethical challenges andwhen deciding on the pros and cons
of terminationofpregnancy, it is important to consider the
normal cognitive capacity and normal intellectual devel-
opment in affected children irrespective of presence and
severity of malformations. The parents of the child de-
scribed as PORD pregnancy A asked for a prenatal diag-
nosis to ascertain whether they should temporarily move
from a very rural area closer to a tertiary care hospital
offering peri- and postpartal fetal medicine and pediatric
specialist care. Fetal sexing using fetal cells circulating in
maternal blood will become available in the foreseeable
future. The parents of PORDpregnancyA considered pre-
natal dexamethasone treatment to avoid the virilization
observed in their firstborn daughter, the index child. This
girl carried homozygous A287P mutations associated
with46,XXDSDbutnormal genital phenotype in affected
46,XY individuals (8). In PORD it is highly likely that the
major part of virilization is driven by the alternative
androgen synthesis pathway (2). Thus, irrespective of
other concerns regarding prenatal dexamethasone
treatment, in a male fetus such a treatment is highly
likely to significantly reduce the substrate flow to the
alternative pathway and consequently result in
undervirilization.
In conclusion, our data demonstrate that diagnosis of
PORD can be established prenatally via GC/MS steroid
analysis of maternal urine, with further data needed on
diagnostic sensitivity and on the differentiation of fetuses
withhomozygousPORmutations fromheterozygous car-
riers. Prenatal ultrasound is helpful in estimating the se-
verity of the PORD-associated skeletalmalformation phe-
notype and appears to correlate with long-term outcome.
These 2 noninvasive diagnostic tools are of significant
promise for the prenatal diagnosis of PORD in pregnan-
cies affected by maternal virilization or fetal malforma-
tions and those occurring after the birth of an index child
with PORD. This diagnostic approach will hopefully fa-
cilitate improved perinatal care and the timely involve-
ment of a multidisciplinary specialist team including en-
docrine expertise.Althoughonan individual patient basis,
urinary steroid profiling of pregnant women with low es-
triol in the triple or quadruple screening test is readily
performed and a powerful tool for the early diagnosis of
PORD,more routine andwidespread use of the technique
for identifying steroid or sterol synthesis disorders such as
PORD, steroid sulfatase deficiency, and Smith-Lemli-
Opitz syndrome in all low-estriol pregnancies is unlikely
to occur because of the costs involved.
Acknowledgments
Address all correspondence and requests for reprints to:
Professor Wiebke Arlt, MD, DSc, FRCP, FMedSci, Centre for
Endocrinology, Diabetes, and Metabolism, School of Clinical
and ExperimentalMedicine, University of Birmingham, Birmingham
B15 2TT, United Kingdom. E-mail: w.arlt@bham.ac.uk.
This work was supported by the Medical Research Council
UKProgramGrant0900567, (toW.A.) andResearchFellowship
G1001964 (to J.I.); the European Community’s Seventh Frame-
work Program (Marie Curie Intra-European Fellowship PIEF-
GA-2008-221058 and Marie Curie European Reintegration
Grant PERG-GA-2010-268270, to N.R.; Collaborative Re-
search Project Grant EuroDSD FP7-GA-2008-201444 (to
W.A.); and the Wellcome Trust (Clinician Scientist Fellowship
GR079865MA, to N.K.).
Disclosure Summary: The authors have nothing to disclose.
References
1. Krone N, Arlt W. Genetics of congenital adrenal hyperplasia. Best
Pract Res Clin Endocrinol Metab. 2009;23:181–192.
2. ArltW,Walker EA, DraperN, et al.Congenital adrenal hyperplasia
caused by mutant P450 oxidoreductase and human androgen syn-
thesis: analytical study. Lancet. 2004;363:2128–2135.
3. FluckCE,TajimaT, PandeyAV, et al.Mutant P450 oxidoreductase
causes disordered steroidogenesis with and without Antley-Bixler
syndrome. Nat Genet. 2004;36:228–230.
4. KroneN,DhirV, IvisonHE,ArltW.Congenital adrenal hyperplasia
and P450 oxidoreductase deficiency. Clin Endocrinol (Oxf). 2007;
66:162–172.
5. Huang N, Pandey AV, Agrawal V, et al. Diversity and function of
mutations in p450 oxidoreductase in patients with Antley-Bixler
syndrome and disordered steroidogenesis. Am J HumGenet. 2005;
76:729–749.
6. Fukami M, Nishimura G, Homma K, et al. Cytochrome P450 oxi-
doreductase deficiency: identification and characterization of bial-
lelic mutations and genotype-phenotype correlations in 35 Japanese
patients. J Clin Endocrinol Metab. 2009;94:1723–1731.
7. Idkowiak J, O’Riordan S, Reisch N, et al. Pubertal presentation in
seven patients with congenital adrenal hyperplasia due to P450 ox-
idoreductase deficiency. J Clin Endocrinol Metab. 2011;96:E453–
E462.
8. Krone N, Reisch N, Idkowiak J, et al.Genotype-phenotype analysis
in congenital adrenal hyperplasia due to P450 oxidoreductase de-
ficiency. J Clin Endocrinol Metab. 2012;97:E257–E267.
J Clin Endocrinol Metab, March 2013, 98(3):E528–E536 jcem.endojournals.org E535
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 27 June 2014. at 06:29 For personal use only. No other uses without permission. . All rights reserved.
9. Kelley RI, Kratz LE, Glaser RL, Netzloff ML, Wolf LM, Jabs EW.
Abnormal sterol metabolism in a patient with Antley-Bixler syn-
drome and ambiguous genitalia. Am J Med Genet. 2002;110:95–
102.
10. Andersson HC, Kratz L, Kelley R.Desmosterolosis presenting with
multiple congenital anomalies and profound developmental delay.
Am J Med Genet. 2002;113:315–319.
11. Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA.
Fluconazole-induced congenital anomalies in three infants.Clin In-
fect Dis. 1996;22:336–340.
12. Aleck KA, Bartley DL.Multiple malformation syndrome following
fluconazole use in pregnancy: report of an additional patient. Am J
Med Genet. 1997;72:253–256.
13. Lee BE, Feinberg M, Abraham JJ, Murthy AR. Congenital malfor-
mations in an infant born to a woman treated with fluconazole.
Pediatr Infect Dis J. 1992;11:1062–1064.
14. Dhir V, Ivison HE, Krone N, et al. Differential inhibition of
CYP17A1 andCYP21A2 activities by the P450 oxidoreductasemu-
tant A287P. Mol Endocrinol. 2007;21:1958–1968.
15. Pandey AV, Kempna P, Hofer G, Mullis PE, Fluck CE.Modulation
of human CYP19A1 activity by mutant NADPH P450 oxidoreduc-
tase. Mol Endocrinol. 2007;21:2579–2595.
16. Idkowiak J,Malunowicz EM,Dhir V, et al.Concomitantmutations
in the P450 oxidoreductase and androgen receptor genes presenting
with 46,XY disordered sex development and androgenization at
adrenarche. J Clin Endocrinol Metab. 2010;95:3418–3427.
17. Shackleton C, Marcos J, Arlt W, Hauffa BP. Prenatal diagnosis of
P450 oxidoreductase deficiency (ORD): a disorder causing low
pregnancy estriol, maternal and fetal virilization, and the Antley-
Bixler syndrome phenotype. Am J Med Genet A. 2004;129A:105–
112.
18. Cragun DL, Trumpy SK, Shackleton CH, et al. Undetectable ma-
ternal serum uE3 and postnatal abnormal sterol and steroid metab-
olism in Antley-Bixler syndrome. Am J Med Genet A. 2004;129A:
1–7.
19. Lao MR, Calhoun BC, Bracero LA, et al. The ability of the qua-
druple test to predict adverse perinatal outcomes in a high-risk ob-
stetric population. J Med Screen. 2009;16:55–59.
20. Dugoff L, Hobbins JC,Malone FD, et al.Quad screen as a predictor
of adverse pregnancy outcome. Obstet Gynecol. 2005;106:260–
267.
21. AuchusRJ,RaineyWE.Adrenarche—physiology, biochemistry and
human disease. Clin Endocrinol (Oxf). 2004;60:288–296.
22. Marcos J, CraigWY, Palomaki GE, et al.Maternal urine and serum
steroidmeasurements to identify steroid sulfatase deficiency (STSD)
in second trimester pregnancies. Prenat Diagn. 2009;29:771–780.
23. ShackletonCH,Marcos J, PalomakiGE, et al.Dehydrosteroidmea-
surements in maternal urine or serum for the prenatal diagnosis of
Smith-Lemli-Opitz syndrome (SLOS). Am J Med Genet A. 2007;
143A:2129–2136.
24. Glass IA, Lam RC, Chang T, Roitman E, Shapiro LJ, Shackleton
CH. Steroid sulphatase deficiency is the major cause of extremely
low oestriol production at mid-pregnancy: a urinary steroid assay
for the discrimination of steroid sulphatase deficiency from other
causes. Prenat Diagn. 1998;18:789–800.
25. Wald N, Densem J, Kennard A. Antenatal screening for Down’s
syndrome. BMJ. 1992;305:1017–1018.
26. Wald N, Kennard A. The value of performing a dating scan on all
women in antenatal screening forDown’s syndrome andneural tube
defects. Ultrasound Obstet Gynecol. 1993;3:3–5.
27. Fang YM, Benn P, Campbell W, Bolnick J, Prabulos AM, Egan JF.
Down syndrome screening in the United States in 2001 and 2007: a
survey of maternal-fetal medicine specialists. Am J Obstet Gynecol
2009;201:97.e1–e5.
28. KimCJ,LinL,HuangN, et al. Severe combinedadrenal andgonadal
deficiency caused by novel mutations in the cholesterol side chain
cleavage enzyme, P450scc. J Clin EndocrinolMetab. 2008;93:696–
702.
29. Malpuech G, Vanlieferinghen P, Dechelotte P, Gaulme J, Labbe A,
Guiot F. Isolated familial adrenocorticotropin deficiency: prenatal
diagnosis by maternal plasma estriol assay.Am JMedGenet. 1988;
29:125–130.
30. Lin L, Philibert P, Ferraz-de-Souza B, et al. Heterozygous missense
mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are asso-
ciated with 46,XY disorders of sex development with normal adre-
nal function. J Clin Endocrinol Metab. 2007;92:991–999.
31. WeintrobN,Drouin J,Vallette-Kasic S, et al.Lowestriol levels in the
maternal triple-marker screen as a predictor of isolated adrenocor-
ticotropic hormone deficiency caused by a newmutation in theTPIT
gene. Pediatrics. 2006;117:e322–e327.
32. Marshall I, Ugrasbul F, Manginello F, et al. Congenital hypopitu-
itarism as a cause of undetectable estriol levels in thematernal triple-
marker screen. J Clin Endocrinol Metab. 2003;88:4144–4148.
33. Pelissier P, Merlin E, Prieur F, et al. [Adrenal hypoplasia congenita:
four new cases in children]. Arch Pediatr. 2005;12:380–384.
34. Peter M, Partsch CJ, Dorr HG, Sippell WG. Prenatal diagnosis of
congenital adrenal hypoplasia. Horm Res. 1996;46:41–45.
35. Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P,
Harada H.Aromatase deficiency in a female who is compound het-
erozygote for two new point mutations in the P450arom gene: im-
pact of estrogens on hypergonadotropic hypogonadism, multicystic
ovaries, and bone densitometry in childhood. J Clin Endocrinol
Metab. 1997;82:1739–1745.
36. Gupta MK, Guryev OL, Auchus RJ. 5-reduced C21 steroids are
substrates for human cytochromeP450c17.ArchBiochemBiophys.
2003;418:151–160.
37. Nyberg DA, Souter VL. Sonographic markers of fetal trisomies:
second trimester. J Ultrasound Med. 2001;20:655–674.
38. Krakow D, Lachman RS, Rimoin DL. Guidelines for the prenatal
diagnosis of fetal skeletal dysplasias.GenetMed. 2009;11:127–133.
E536 Reisch et al Prenatal Diagnosis of PORD J Clin Endocrinol Metab, March 2013, 98(3):E528–E536
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 27 June 2014. at 06:29 For personal use only. No other uses without permission. . All rights reserved.
